GlassScriptPhysician profile
Amelia Davis
NPI 1861714230
$1,250.03
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $201.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $177.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $152.87 | 2019-2020 | |
| Indivior INC. | $145.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $138.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $95.18 | 2019 | |
| Lundbeck LLC | $87.42 | 2019-2020 | |
| Allergan, INC. | $55.25 | 2019-2020 | |
| Shire North American Group INC | $48.10 | 2019 | |
| Ironshore Pharmaceuticals INC. | $42.42 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $32.31 | 2019 | |
| Avanir Pharmaceuticals, INC. | $31.39 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $15.61 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2020 | |
| Neurocrine Biosciences, INC. | $13.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.